Oprd1-flox Mouse

OPRD1 encodes the delta-opioid receptor, which has multiple functions including regulating reward pathways [1]. This receptor is a key component in the body's opioid-related physiological processes, and its associated pathways play a significant role in the body's response to various stimuli. Genetic models, such as gene knockout models, can be valuable in further exploring the gene's functions.

The OPRD1 gene contains over 2,000 verified genetic variants, with rs1042114 disrupting receptor maturation and rs569356 affecting its expression [1]. Polymorphisms in this gene have been associated with multiple human diseases. For instance, three variants in intron 1 (rs2236861, rs2236857, and rs3766951) are associated with opioid addiction in several independent populations [1]. A haplotype block containing rs569356 and rs533123 is associated with anorexia, though the mechanisms are unknown [1]. Rs1042114 has been linked to Alzheimer's disease, as the variant allele reduces production of beta-amyloid plaques [1]. Additionally, OPRD1 rs569356 affects plasma norbuprenorphine levels and craving/withdrawal symptoms in opioid-use-disorder patients [2]. Some OPRD1 intronic variants associated with opioid addiction are cis-eQTLs for PHACTR4, a gene involved in cytoskeletal dynamics [3]. In Han Chinese heroin-dependent patients, the rs2234918 minor C allele is over-represented in the HD group, and rs2236857 T/T homozygotes have more severe stress [4]. The rs678849 variant influences the outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients [5]. And certain OPRD1 SNPs and a specific haplotype are associated with heroin dependence [6].

In conclusion, OPRD1 plays a crucial role in regulating reward pathways and is associated with various human diseases such as opioid addiction, anorexia, and Alzheimer's disease. Research using genetic models, especially when considering its genetic polymorphisms, can help in understanding its role in these disease conditions, potentially leading to new therapeutic strategies for these disorders.